Our commitment to protect the health of the planet is closely tied to our mission to improve the health of patients. As we continue to grow and expand our operations, we keep the environment front of mind. Our environmental targets reflect our ambitions to mitigate our GHG emissions, increase our use of renewable energy, minimize waste and enhance water stewardship. Our efforts are guided by our global EHS policy, which Regeneron’s senior management team is accountable for enforcing across all teams. In 2022, we conducted an enterprise-wide assessment to better understand the key drivers of our GHG emissions and forecast how they might evolve as we continue to grow. We also held a series of cross-functional, internal workshops to identify opportunities to reduce our emissions. We used these insights to develop an action plan to meet our existing targets and prepare for the future. Regeneron continues our work to deliver needed new medicines to patients. Our pipeline is composed of primarily homegrown therapeutics and powered by end-to-end research and development capabilities. Our team of researchers continues to transform and accelerate the traditional drug discovery process, enabled by our proprietary VelociSuite technologies and informed by discoveries being made in our RGC and across our R&D groups. We are expanding our technological toolkit with new genetic medicine capabilities to bolster our portfolio and diversify the diseases we can treat in the future. Our Global Development team brings investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. To facilitate continued innovation, protect patients and promote collaboration, we actively protect intellectual property (IP) rights in our innovations and discoveries. It can cost billions of dollars and many years to discover, test, validate and obtain approval for just a single biologic medicine. By protecting our IP, we prevent others from inappropriately benefiting from our hard work and investment. IP also helps ensure patients receive authentic, safe and effective treatments by precluding others from making substandard copies or importing counterfeits of our medicines. It is similarly foundational in the promotion of global collaborations by allowing us to openly share our ideas and advancements with the hopes of spurring additional innovations. Our patent portfolio and IP strategy are subject to close review by senior management on a regular basis. Our robust governance, policies and procedures and strong moral compass inform the work we do every day at Regeneron. The rigor of our scientific purpose is reflected in how we operate our business, from our clinical trials to product quality and supply chain management — all with a focus on delivering the best outcomes for patients. Strong corporate governance is the cornerstone to our success and underpins our long-term business strategy. We believe that good corporate governance promotes the long-term interests of stakeholders and helps build trust in Regeneron.